PAGE 06 · PUBLISHER
An editorial project, not a clinic.
Who publishes this site, what it does, and what it deliberately does not do.
What this site is
TB-500 Legal is an independent editorial project that publishes summaries of the peer-reviewed research literature and the regulatory record on Thymosin Beta-4 and its synthetic seven-amino-acid fragment Ac-LKKTETQ-OH. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and publicly published regulatory documents.
The site exists because the regulatory record on TB-500 is dispersed across multiple jurisdictions and authorities — the FDA interim 503A bulks list, the World Anti-Doping Agency annual Prohibited List, the International Federation of Horseracing Authorities International Agreement, the US Anti-Doping Agency sanction archive, agency warning-letter notices — and is rarely read together. The editorial conceit of the site is to read those documents the way a customs officer reads a passport: jurisdiction by jurisdiction, stamp by stamp, with the regulatory geography in clear view.
The domain name carries the word 'legal' as editorial framing — the publisher's stance toward the literature, focused on jurisdictional questions about a research peptide. It is not a claim that the site provides legal counsel, regulatory consulting, or any form of professional service. The site offers no consultation, no prescription, no representation, and no advisory relationship of any kind.
Editorial standards
Every quantitative claim on the site is cited to a specific peer-reviewed study, a registered clinical trial, or a regulatory document of record. Where the underlying record is ambiguous — for example, where vendor literature treats the synthetic TB-500 fragment as interchangeable with full-length Tβ4 while the structural biology distinguishes them — the ambiguity is preserved in the editorial copy rather than resolved by inference. Where studies have produced negative results, including the porcine cardiac IR-injury work that did not replicate the rodent cardiac findings, those negative results are reported.
The site does not promote any vendor, supplier, compounding pharmacy, telehealth platform, or product. It does not link to commercial sources of TB-500 or any related research chemical. It does not solicit consultations, prescriptions, or purchases. The outbound links on the site are limited to PubMed, PubMed Central, the National Institutes of Health, ClinicalTrials.gov, peer-reviewed journal websites, the FDA, WADA, USADA, and equivalent regulatory and scientific institutions.
The editorial contract of this site is a familiar one in scientific journalism: document the published record, report the regulatory findings, preserve the negative results and the contested claims alongside the favorable ones, and take no position on human use that the underlying scientific and regulatory record does not already take. An independent editorial survey of the published record — not a clinic, not a vendor, not legal counsel.
What we deliberately do not do
We do not name a 'medical team,' a 'clinical advisor,' a 'reviewing physician,' or any individual person — fictional or real — as the author or editor of this site. The site is published anonymously as an editorial project, in line with the publisher's stated role as a commentator on the regulatory and research record rather than a participant in clinical care.
We do not provide medical advice, treatment recommendations, dosing guidance for human use, prescriptions, consultations, or any service that requires a licensed health-care professional. We do not refer readers to specific clinics, vendors, suppliers, or compounding pharmacies. We do not assess the legality of any specific transaction, possession, importation, or use of TB-500 in any specific jurisdiction or circumstance — those determinations require a licensed attorney with knowledge of the reader's situation.
The regulatory findings documented on the site are the published findings of the relevant agencies, current as of the publication date noted on each page. Regulatory status can and does change. Readers seeking the current authoritative status of any substance in any jurisdiction should consult the relevant agency directly.